tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating
PremiumRatingsPromising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating
2M ago
Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo
Premium
The Fly
Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo
2M ago
RAPT Therapeutics: Anticipated Growth Driven by Strategic Partnerships and Promising Clinical Developments
Premium
Ratings
RAPT Therapeutics: Anticipated Growth Driven by Strategic Partnerships and Promising Clinical Developments
2M ago
Rapt Therapeutics target adjusted to $24 from $3 at Clear Street
PremiumThe FlyRapt Therapeutics target adjusted to $24 from $3 at Clear Street
2M ago
Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan
Premium
The Fly
Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan
2M ago
LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset
Premium
The Fly
LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset
2M ago
Rapt Therapeutics target adjusted to $27 from $6 at H.C. Wainwright
PremiumThe FlyRapt Therapeutics target adjusted to $27 from $6 at H.C. Wainwright
3M ago
RAPT Therapeutics Unveils Plans for RPT904 Development
Premium
Company Announcements
RAPT Therapeutics Unveils Plans for RPT904 Development
3M ago
RAPT Therapeutics Expands Board with New Appointments
Premium
Company Announcements
RAPT Therapeutics Expands Board with New Appointments
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100